Dosing is now underway in an IPF clinical trial testing the inhaled therapy LTI-03, following the lifting of an FDA hold late last year.

Columnist Sam Kirton has developed some strategies to make the roughly 90-minute commute to his IPF doctor appointments more manageable.

The experimental IPF therapy deupirfenidone was granted orphan drug designation by regulatory agencies in the U.S. and the European Union.

A recent car accident prompted columnist Kylene Henderson and her husband, Donnie, who has PF, to consider how to prepare for emergencies.

Rare Disease Day in February is an important time to raise awareness about a club no one asked to join, writes columnist Sam Kirton.

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center will collaborate with GSK to develop stem cell-based models to better understand pulmonary fibrosis and ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...